Home > Insider Trading > Filing (0001250853-20-000086)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1561743	Kindred Biosciences Inc.	KIN	Pharmaceutical Preparations (2834)	461160142

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1593865	Denise Bevers	C/O Kindred Biosciences, Inc. 1555 Bayshore Highway, Suite 200 Burlingame CA 94010		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-10-07	12,508	$0.32	12,508	No	4	M	Indirect	By SD Scientific, Inc.
Common Stock	Disposition	2020-10-07	12,508	$5.01	0	No	4	S	Indirect	By SD Scientific, Inc.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Indirect	By SD Scientific, Inc.
No	4	S	Indirect	By SD Scientific, Inc.

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2020-10-07	12,508	$0.00	12,508	$0.32

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
15,502	2013-02-04	2023-02-04	No	4	M	Indirect

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	143,835	Direct

Footnotes

Held by SD Scientific, Inc. ("SD Scientific"). The Reporting Person is a co-director and co-stockholder of SD Scientific and, as such shares voting and dispositive power over such shares held by SD Scientific but disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.00 to $5.01, inclusive. The Reporting Person undertakes to provide to Kindred Biosciences, Inc., any security holder of Kindred Biosciences, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.